TCV-309 (chloride) manufacturers
- TCV-309 chloride
-
- $1160.00 / 50mg
-
2025-08-21
- CAS:121494-09-5
- Min. Order:
- Purity:
- Supply Ability: 10g
- TCV-309 chloride
-
- $1160.00 / 50mg
-
2025-07-22
- CAS:121494-09-5
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | TCV-309 (chloride) Basic information |
| | TCV-309 (chloride) Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO : ≥ 6.3 mg/mL (10.00 mM) | | form | Solid | | color | Light yellow to yellow |
| | TCV-309 (chloride) Usage And Synthesis |
| Uses | TCV-309 chloride is a potent and specific platelet activating factor (PAF) antagonist. TCV-309 chloride specifically inhibits PAF-induced aggregation of rabbit and human platelets, and [3H]PAF binding to rabbit platelet microsomes with IC50 values of 33 nM, 58 nM and 27 nM, respectively. TCV-309 chloride has beneficial effects in anaphylactic shock[1][2]. | | in vivo | In rats, TCV-309 selectively inhibits the PAF-induced hypotension, hemoconcentration and death with ED50 values of 2.7, 6.4 and 1.7 micrograms/kg (i.v.), respectively. TCV-309 most potently protects mice from death induced by PAF and due to anaphylactic shock with ED50 values of 2.1 and 2.6 micrograms/kg (i.v.), respectively[1].
TCV-309 chloride also reversed PAF-induced hypotension and endotoxin-induced hypotension in rats with ED50 values of 3.3 and 1.2 micrograms/kg (i.v.), respectively[1].
| | References | [1] Terashita Z et al. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents. J Pharmacol Exp Ther. 1992 Feb;260(2):748-55. PMID:1738121
[2] M Poeze, et al. Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II trial. TCV-309 Septic Shock Study Group. Shock. 2000 Oct;14(4):421-8. DOI:10.1097/00024382-200014040-00001 |
| | TCV-309 (chloride) Preparation Products And Raw materials |
|